Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 23;13(8):1441.
doi: 10.3390/v13081441.

Serological Evidence of Widespread Zika Transmission across the Philippines

Joseph R Biggs  1 , Ava Kristy Sy  2   3 , Oliver J Brady  4   5 , Adam J Kucharski  4   5 , Sebastian Funk  4   5 , Yun-Hung Tu  6 , Mary Anne Joy Reyes  2   3 , Mary Ann Quinones  2   3 , William Jones-Warner  1 , James Ashall  1 , Ferchito L Avelino  7 , Nemia L Sucaldito  7 , Amado O Tandoc  2 , Eva Cutiongco-de la Paz  8   9 , Maria Rosario Z Capeding  3   8 , Carmencita D Padilla  8   9 , Martin L Hibberd  1   8   9 , Julius Clemence R Hafalla  1
Affiliations

Serological Evidence of Widespread Zika Transmission across the Philippines

Joseph R Biggs et al. Viruses. .

Abstract

Zika virus (ZIKV) exposure across flavivirus-endemic countries, including the Philippines, remains largely unknown despite sporadic case reporting and environmental suitability for transmission. Using laboratory surveillance data from 2016, 997 serum samples were randomly selected from suspected dengue (DENV) case reports across the Philippines and assayed for serological markers of short-term (IgM) and long-term (IgG) ZIKV exposure. Using mixture models, we re-evaluated ZIKV IgM/G seroprevalence thresholds and used catalytic models to quantify the force of infection (attack rate, AR) from age-accumulated ZIKV exposure. While we observed extensive ZIKV/DENV IgG cross-reactivity, not all individuals with active DENV presented with elevated ZIKV IgG, and a proportion of dengue-negative cases (DENV IgG-) were ZIKV IgG-positive (14.3%, 9/63). We identified evidence of long-term, yet not short-term, ZIKV exposure across Philippine regions (ZIKV IgG+: 31.5%, 314/997) which was geographically uncorrelated with DENV exposure. In contrast to the DENV AR (12.7% (95%CI: 9.1-17.4%)), the ZIKV AR was lower (5.7% (95%CI: 3-11%)) across the country. Our results provide evidence of widespread ZIKV exposure across the Philippines and suggest the need for studies to identify ZIKV infection risk factors over time to better prepare for potential future outbreaks.

Keywords: Philippines; Zika; dengue; diagnostics; force of infection; serology.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Figures

Figure 1
Figure 1
Map of the Philippines showing the location of the 102 DRUs where dengue patients were sampled from across all 17 regions during 2016. Urban zones: >1500 persons per km2. Non-urban zones: <1500 persons per km2.
Figure 2
Figure 2
ZIKV and DENV antibody responses among the study population. (A) Distribution of ZIKV and DENV IgM and IgG antibody responses (ELISA values) among the study population. Red line: probability of being ZIKV IgG seropositive according to the mixture model. (B) Scatterplot of ZIKV versus DENV IgG ELISA values among the study population. (C) Violin plots of ZIKV and DENV IgG ELISA values among those classified as DENV primary, post-primary, historical and negative. White circles: median, thick black bar: IQR. Grey dash: IgG seroprevalence thresholds (ZIKV IgG: 0.57 ELISA values, DENV IgG: 0.22 ELISA values). (D) Scatterplots of ZIKV versus DENV IgG ELISA values among DENV primary, post-primary, historical and negative cases plotted on a log scale. Orange dash: DENV IgG seroprevalence threshold (0.22 ELISA values). Blue dash: ZIKV IgG seroprevalence threshold (0.57 ELISA values).
Figure 3
Figure 3
ZIKV IgG seroprevalence patterns among the study population. (A) ZIKV IgG seroprevalence by disease day among all, and age-stratified, post-primary dengue cases. (B) ZIKV IgG seroprevalence among post-primary and historical dengue cases. Vertical lines: 95%CI (confidence interval), (* non-overlapping 95%CI).
Figure 4
Figure 4
Immunoepidemiology of ZIKV and DENV across the Philippines during 2016. (A) Regional ZIKV/DENV IgG seroprevalence among those reporting without active DENV infections. (B) ZIKV/DENV age seroprevalence across the Philippines and stratified by urban/non-urban areas. ARs (attack rates) were calculated from the seroconversion rate (SCR) estimated among those without current DENV infections (historical and negative DENV cases) using reverse catalytic models. Black dots: observed age IgG seroprevalence. Curve: predicted age IgG seroprevalence. Dash: 95%CI.
See this image and copyright information in PMC

References

    1. World Health Organization Zika Epidemiological Update Report. [(accessed on 14 July 2021)]; Available online: https://www.who.int/emergencies/diseases/zika/zika-epidemiology-update-j....
    1. Lowe R., Barcellos C., Brasil P., Cruz O.G., Honório N.A., Kuper H., Carvalho M.S. The Zika Virus Epidemic in Brazil: From Discovery to Future Implications. Int. J. Environ. Res. Public Health. 2018;15:96. doi: 10.3390/ijerph15010096. - DOI - PMC - PubMed
    1. Cao-Lormeau V.-M., Blake A., Mons S., Lastère S., Roche C., Vanhomwegen J., Dub T., Baudouin L., Teissier A., Larre P., et al. Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: A case-control study. Lancet. 2016;387:1531–1539. doi: 10.1016/S0140-6736(16)00562-6. - DOI - PMC - PubMed
    1. Brady O.J., Osgood-Zimmerman A., Kassebaum N.J., Ray S.E., de Araújo V.E.M., Da Nóbrega A.A., Frutuoso L.C.V., Lecca R.C.R., Stevens A., Zoca de Oliveira B., et al. The association between Zika virus infection and microcephaly in Brazil 2015-2017: An observational analysis of over 4 million births. PLoS Med. 2019;16:e1002755. doi: 10.1371/journal.pmed.1002755. - DOI - PMC - PubMed
    1. Lessler J., Chaisson L.H., Kucirka L.M., Bi Q., Grantz K., Salje H., Carcelen A.C., Ott C.T., Sheffield J.S., Ferguson N.M., et al. Assessing the global threat from Zika virus. Science. 2016;353:aaf8160. doi: 10.1126/science.aaf8160. - DOI - PMC - PubMed

Publication types

MeSH terms